Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.

Thoratec Corp.’s continued rapid growth is driven by implants of HeartMate II left-ventricular assist device in heart failure patients ineligible for a transplant.

During its Feb. 5 fourth-quarter earnings call, Thoratec CFO Gerhard Burbach explained that LVAD implants in transplant-ineligible patients – known...

More from Archive

More from Medtech Insight